These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7763298)

  • 21. Progress toward inhibitors of metallo-β-lactamases.
    McGeary RP; Tan DT; Schenk G
    Future Med Chem; 2017 May; 9(7):673-691. PubMed ID: 28504895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanisms of resistance to beta-lactam inhibitors of beta-lactamases].
    Blázquez J
    Rev Esp Quimioter; 1998 Dec; 11(4):368-9. PubMed ID: 10336318
    [No Abstract]   [Full Text] [Related]  

  • 23. The structures and catalytic mechanisms of active-site serine beta-lactamases.
    Lamotte-Brasseur J; Knox J; Kelly JA; Charlier P; Fonzé E; Dideberg O; Frére JM
    Biotechnol Genet Eng Rev; 1994; 12():189-230. PubMed ID: 7727028
    [No Abstract]   [Full Text] [Related]  

  • 24. [New broad-spectrum beta-lactamases].
    Fernández de Aránguiz A
    Enferm Infecc Microbiol Clin; 1992 Nov; 10(9):511-3. PubMed ID: 1489789
    [No Abstract]   [Full Text] [Related]  

  • 25. Refined crystal structure of beta-lactamase from Citrobacter freundii indicates a mechanism for beta-lactam hydrolysis.
    Oefner C; D'Arcy A; Daly JJ; Gubernator K; Charnas RL; Heinze I; Hubschwerlen C; Winkler FK
    Nature; 1990 Jan; 343(6255):284-8. PubMed ID: 2300174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical use of DD-peptidase 64-575 for the assay of inhibition activity of natural and synthetic beta-lactam compounds.
    Solecka J; Lysek R; Furman B; Chmielewski M; Kurzatkowski W
    Acta Pol Pharm; 2003; 60(2):115-8. PubMed ID: 13678318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using X-ray diffraction results and computer graphics to design beta-lactams.
    Kelly JA; Knox JR; Moews PC; Frere JM; Ghuysen JM
    Kansenshogaku Zasshi; 1988 Mar; 62 Suppl():182-91. PubMed ID: 3138345
    [No Abstract]   [Full Text] [Related]  

  • 28. [Bacterial resistance to beta-lactam antibiotics].
    Roy C
    Med Clin (Barc); 1983 Sep; 81(7):299-301. PubMed ID: 6606092
    [No Abstract]   [Full Text] [Related]  

  • 29. Class B beta-lactamases: the importance of being metallic.
    Cricco JA; Vila AJ
    Curr Pharm Des; 1999 Nov; 5(11):915-27. PubMed ID: 10539996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SQ 26,776: in-vitro antibacterial activity and susceptibility to beta-lactamases.
    Phillips I; King A; Shannon K; Warren C
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():103-10. PubMed ID: 6976960
    [No Abstract]   [Full Text] [Related]  

  • 31. On the importance of a methyl group in beta-lactamase evolution: free energy profiles and molecular modeling.
    Bernstein NJ; Pratt RF
    Biochemistry; 1999 Aug; 38(32):10499-510. PubMed ID: 10441146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delta 2- and delta 3-cephalosporins, penicillinate and 6-unsubstituted penems. Intrinsic reactivity and interaction with beta-lactamases and D-alanyl-D-alanine-cleaving serine peptidases.
    Frère JM; Kelly JA; Klein D; Ghuysen JM; Claes P; Vanderhaeghe H
    Biochem J; 1982 Apr; 203(1):223-34. PubMed ID: 6980645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comment on: Redefining extended-spectrum beta-lactamases: balancing science and clinical need.
    Bush K; Jacoby GA; Amicosante G; Bonomo RA; Bradford P; Cornaglia G; Garau J; Giamarellou H; Jarlier V; Martinez-Martinez L; Miriagou V; Palzkill T; Pascual A; Rodriguez-Baño J; Rossolini GM; Sougakoff W; Vatopoulos A
    J Antimicrob Chemother; 2009 Jul; 64(1):212-3; author reply 213-5. PubMed ID: 19318363
    [No Abstract]   [Full Text] [Related]  

  • 34. Activity of beta-lactamases against beta-lactams.
    Stratton CW
    J Antimicrob Chemother; 1988 Jul; 22 Suppl A():23-35. PubMed ID: 3062002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria.
    Dalhoff A; Nasu T; Okamoto K
    Chemotherapy; 2003 Jul; 49(4):172-83. PubMed ID: 12886052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta-secondary and solvent deuterium kinetic isotope effects on catalysis by the Streptomyces R61 DD-peptidase: comparisons with a structurally similar class C beta-lactamase.
    Adediran SA; Pratt RF
    Biochemistry; 1999 Feb; 38(5):1469-77. PubMed ID: 9931012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational analysis of active-site residues of the enterococcal D-ala-D-Ala dipeptidase VanX and comparison with Escherichia coli D-ala-D-Ala ligase and D-ala-D-Ala carboxypeptidase VanY.
    Lessard IA; Walsh CT
    Chem Biol; 1999 Mar; 6(3):177-87. PubMed ID: 10074467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trapping and hydrolysis are not mutually exclusive mechanisms for beta-lactamase-mediated resistance.
    Sanders CC; Sanders WE
    J Antimicrob Chemother; 1986 Jan; 17(1):121-2. PubMed ID: 3485090
    [No Abstract]   [Full Text] [Related]  

  • 39. Sch 29482: in-vitro antibacterial activity and susceptibility to beta-lactamases.
    Phillips I; King A; Shannon K; Warren C
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():25-30. PubMed ID: 6977532
    [No Abstract]   [Full Text] [Related]  

  • 40. The D-methyl group in beta-lactamase evolution: evidence from the Y221G and GC1 mutants of the class C beta-lactamase of Enterobacter cloacae P99.
    Adediran SA; Zhang Z; Nukaga M; Palzkill T; Pratt RF
    Biochemistry; 2005 May; 44(20):7543-52. PubMed ID: 15895997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.